MedTrace Logo

Phase II Gleevec Idiopathic Hypereosinophilic Syndrome

NCT00230334 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2021-05-10

No results posted yet for this study

Summary

The purpose of the trial is to determine the safety and efficacy of Gleevec" in idiopathic hypereosinophilic syndrome (HES) and to characterize the molecular basis for the therapeutic benefit of Gleevec" in HES.

Conditions

  • Eosinophilia
  • Hypereosinophilic Syndrome

Interventions

DRUG

Gleevec

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Steven E. Coutre

    lead OTHER

Principal Investigators

  • Steven E Coutre · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-12
Primary Completion
2006-12-29
Completion
2007-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00230334 on ClinicalTrials.gov